SCHEMBL17938602

SCHEMBL17938602

O=C(COc1ccc(C(=O)c2ccccc2)cc1)NC1CCN(Cc2ccccc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADIPOR2 Q86V24 1/20 1.00
ADIPOR1 Q96A54 1/20 1.00
POLB P06746 1/20 0.83
USP2 O75604 1/20 0.79
SMN1; SMN2 Q16637 4/20 0.69
LMNA P02545 3/20 0.69
ALDH1A1 P00352 2/20 0.69
MEN1 O00255 1/20 0.69
KMT2A Q03164 1/20 0.69
MAPK1 P28482 1/20 0.68
L3MBTL1 Q9Y468 1/20 0.65
SIGMAR1 Q99720 2/20 0.62
MCHR1 Q99705 2/20 0.59
MAPT P10636 1/20 0.58
FAAH O00519 1/20 0.58
BCHE P06276 1/20 0.58
ACHE P22303 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17950883 0.95 ADIPOR2 (0.90) ADIPOR2ADIPOR1POLBUSP2SMN1; SMN2
SCHEMBL17946118 0.94 ADIPOR2 (0.88) ADIPOR2ADIPOR1POLBUSP2SMN1; SMN2
SCHEMBL24514564 0.90 ADIPOR2 (0.82) ADIPOR2ADIPOR1POLBUSP2SMN1; SMN2
SCHEMBL24514572 0.90 ADIPOR2 (0.81) ADIPOR2ADIPOR1POLBUSP2SMN1; SMN2
SCHEMBL24514563 0.89 POLB (0.86) ADIPOR2ADIPOR1POLBUSP2SMN1; SMN2
SCHEMBL17946047 0.89 POLB (0.91) ADIPOR2ADIPOR1POLBUSP2SMN1; SMN2
SCHEMBL21064273 0.88 ADIPOR2 (0.78) ADIPOR2ADIPOR1POLBUSP2SMN1; SMN2
SCHEMBL25568932 0.88 ADIPOR2 (0.77) ADIPOR2ADIPOR1POLBUSP2SMN1; SMN2
SCHEMBL17945987 0.88 POLB (0.84) ADIPOR2ADIPOR1POLBUSP2SMN1; SMN2
SCHEMBL20662532 0.87 ADIPOR2 (0.77) ADIPOR2ADIPOR1POLBUSP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250295678-A1 ULTRA LOW DOSAGE ZOLEDRONIC ACID FOR TREATMENT OF RETINAL DISEASE THE WISCONSIN ALUMNI RESEARCH FOUNDATION 2025-09-25 US claimed
CN-120189494-A Use of adiponectin and adiponectin receptor agonists for the treatment of amyotrophic lateral sclerosis 河北医科大学第二医院 2025-06-24 CN claimed
EP-4522177-A1 ULTRA LOW DOSAGE ZOLEDRONIC ACID FOR TREATMENT OF RETINAL DISEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-03-19 EP claimed
US-20240288450-A1 SYSTEMS AND METHODS FOR MONITORING AND TREATING STROKE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-08-29 US claimed
US-20240016788-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETIC AND POSTMENOPAUSAL OSTEOPOROSIS, CONTAINING ADIPORON PNP BIOPHARM CO LTD (KR) 2024-01-18 US claimed
CN-117337167-A Compositions and methods relating to hair loss 阿拉斯廷护肤品股份有限公司 2024-01-02 CN claimed
EP-4294533-A1 COMPOSITIONS AND METHODS RELATING TO ALOPECIA Alastin Skincare, Inc. (US) 2023-12-27 EP claimed
US-20230390355-A1 COMPOSITIONS AND METHODS RELATING TO ALOPECIA ALASTIN Skincare, Inc. (US) 2023-12-07 US claimed
WO-2023220136-A1 ULTRA LOW DOSAGE ZOLEDRONIC ACID FOR TREATMENT OF RETINAL DISEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-11-16 WO claimed
CN-116622628-A Serum-free culture medium for producing exosomes by mesenchymal stem cells, and preparation and application thereof 华东理工大学 2023-08-22 CN claimed
WO-2022266039-A1 SYSTEMS AND METHODS FOR MONITORING AND TREATING STROKE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2022-12-22 WO claimed
CN-115245512-A Method for intervening oxidative stress of oral active AdipoRon on liver of type II diabetic mouse 温州医科大学 2022-10-28 CN claimed
WO-2022177881-A1 COMPOSITIONS AND METHODS RELATING TO ALOPECIA ALASTIN Skincare, Inc. (US) 2022-08-25 WO claimed
US-20220249458-A1 Agonists Of Adiponectin BAYER AKTIENGESELLSCHAFT (DE) 2022-08-11 US claimed
WO-2022103197-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETIC AND POSTMENOPAUSAL OSTEOPOROSIS, CONTAINING ADIPORON (주)피앤피바이오팜 2022-05-19 WO claimed
CN-114073667-A Methods and systems for treating obesity-related diseases with orally active adiplon 温州医科大学 2022-02-22 CN claimed
EP-3946416-A2 AGONISTS OF ADIPONECTIN Bayer Aktiengesellschaft (DE) 2022-02-09 EP claimed
EP-3431468-B1 USE OF ADIPONECTIN RECEPTOR AGONISTS IN TREATING DEPRESSION, ANXIETY AND NEUROINFLAMMATION CENTRE NAT RECH SCIENT (FR) 2021-06-09 EP claimed
WO-2020201195-A2 AGONISTS OF ADIPONECTIN BAYER AKTIENGESELLSCHAFT (DE) 2020-10-08 WO claimed
EP-3431468-A1 USE OF ADIPONECTIN RECEPTOR AGONISTS IN TREATING DEPRESSION, ANXIETY AND NEUROINFLAMMATION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-01-23 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250295678-A1 ULTRA LOW DOSAGE ZOLEDRONIC ACID FOR TREATMENT OF RETINAL DISEASE FDPS, SMPD1, SMPD2 ADIPOR2 566/4885ADIPOR1 362/4885POLB 3643/4885
US-20220249458-A1 Agonists Of Adiponectin ADIPOR1, ADIPOR2, FABP4 ADIPOR2 2/4885ADIPOR1 1/4885POLB 4727/4885
US-20240016788-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETIC AND POSTMENOPAUSAL OSTEOPOROSIS, CONTAINING ADIPORON ADIPOR1, ADIPOR2, PPARA ADIPOR2 2/4885ADIPOR1 1/4885POLB 3567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.